As part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, FDA granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
